The use of flavonoids such as oroxylin A can effectively reverse IM resistance in CML within the bone marrow microenvironment by enhancing the sensitivity of CML cells to IM therapy through the regulation of the CXCL12/CXCR7 pathway. The gene discussed is ACKR3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.